Quizartinib (Synonyms: AC220; AC708)

Name: Quizartinib
Brand: MedChemExpress
SKU: HY-13001
Rating: 5.0 (34 reviews)

Cat. No.: HY-13001 Purity: 98.83%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a K_d of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC₅₀s of 4.2 and 1.1 nM, respectively. Quizartinib can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib induces apoptosis.

For research use only. We do not sell to patients.

Quizartinib Chemical Structure

CAS No. : 950769-58-1

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 81	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 81	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 66	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 92	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 158	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 264	In-stock	Estimated Time of Arrival: December 31
200 mg	USD 462	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 858	In-stock	Estimated Time of Arrival: December 31
1 g		Get quote
5 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 34 publication(s) in Google Scholar

Other Forms of Quizartinib:

Quizartinib dihydrochloride Get quote
Quizartinib (Standard) Get quote

31 Publications Citing Use of MCE Quizartinib

: Quizartinib purchased from MedChemExpress. Usage Cited in: J Med Chem. 2017 Oct 26;60(20):8407-8424. [Abstract]; Doseresponsive immunoblotting of the signaling pathway with the cells extracted from tumor tissues of the experimental animal after the 14 and 7 (AC220) treatments.

: Quizartinib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 Jul 26;7(30):47018-47032. [Abstract]; A. The established 32D cells are treated with Quizartinib for 2h, followed by 10 ng/mL FL stimulation for 10 minutes. Wt-FLT3 and mutant FLT3 are immunoprecipitated by each tag as indicated and subjected to Western blot. Phosphorylation levels of FLT3, STAT5, AKT and MAPK are examined. B. 32D cells are treated with Quizartinib at the indicated concentrations in the presence or absence of 10 ng/mL FL for 2 hours. Phosphorylation levels of FLT3, STAT5, AKT and MAPK are detected by Western blot.

: Quizartinib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2014 Feb 10;25(2):226-42. [Abstract]; Western blot for indicated proteins on lysates from FLT3-ITD-positive primary murine cells expressing either wild-type (WT) or constitutive active (SYK-TEL) SYK and treated for eight hours with indicated doses of AC220.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Kd: 1.6±0.7 nM (Flt3)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	> 10000 nM Compound: AC220	Toxicity against human A375 cells after 72 hrs by cell titer-blue assay Toxicity against human A375 cells after 72 hrs by cell titer-blue assay	[PMID: 19654408]
BaF3	GI₅₀	< 0.0003 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	< 0.0003 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells expressing TEL-fused FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells expressing TEL-fused FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	< 0.0003 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835N mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835N mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	< 0.0003 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835G mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835G mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	< 0.0003 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835A mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835A mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	< 0.0003 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835H mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835H mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	< 0.0003 μM Compound: 7	Antiproliferative activity against TEL-fused PDGFRalpha-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused PDGFRalpha-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	> 10 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	IC₅₀	> 1000 nM Compound: AC220	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-F691L mutant measured after 72 hrs by MTT assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-F691L mutant measured after 72 hrs by MTT assay	[PMID: 30939008]
BaF3	IC₅₀	> 1000 nM Compound: AC220	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835V mutant measured after 72 hrs by MTT assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835V mutant measured after 72 hrs by MTT assay	[PMID: 30939008]
BaF3	IC₅₀	> 1000 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	GI₅₀	> 10000 nM Compound: AC-220	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	> 10000 nM Compound: AC-220	Antiproliferative activity against mouse Ba/F3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	0.002 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835Y mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835Y mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.0044 μM Compound: 7	Antiproliferative activity against TEL-fused PDGFRbeta-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused PDGFRbeta-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.011 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835V mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835V mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.012 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835del mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835del mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.017 μM Compound: 7	Antiproliferative activity against TEL-fused cKIT-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused cKIT-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.024 μM Compound: 7	Antiproliferative activity against TEL-fused CSF1R-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused CSF1R-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.028 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835Y mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835Y mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.056 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835I mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835I mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.11 μM Compound: 7	Antiproliferative activity against TEL-fused DDR2-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused DDR2-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.12 μM Compound: 7	Antiproliferative activity against TEL-fused DDR1-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused DDR1-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.13 μM Compound: 7	Antiproliferative activity against TEL-fused RET-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused RET-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.27 μM Compound: 7	Antiproliferative activity against TEL-fused FLT4-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused FLT4-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.3 nM Compound: 3	Inhibition of FLT3 ITD mutant expressed in human BaF3 cells assessed as reduction in cell growth incubated for 72 hrs by CCK8 assay Inhibition of FLT3 ITD mutant expressed in human BaF3 cells assessed as reduction in cell growth incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
BaF3	GI₅₀	0.37 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-K663Q mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-K663Q mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.4 μM Compound: 7	Antiproliferative activity against TEL-fused LCK-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused LCK-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.6 nM Compound: AC-220	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	1.452 μM Compound: Quiz	Growth inhibition of mouse BA/F3 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of mouse BA/F3 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
BaF3	GI₅₀	12.9 nM Compound: AC-220	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	IC₅₀	121 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells harboring FLT3-D835F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-D835F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 36638621]
BaF3	IC₅₀	133.2 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-F691L mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-F691L mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	IC₅₀	14.97 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-Y842H mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-Y842H mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	GI₅₀	1659.5 nM Compound: 3	Cytotoxicity against human BAF3 cells assessed as growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against human BAF3 cells assessed as growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
BaF3	IC₅₀	2 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 36638621]
BaF3	GI₅₀	2.2 nM Compound: AC-220	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	IC₅₀	27.09 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells harboring FLT3-TEL-D835V mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-TEL-D835V mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	IC₅₀	3.52 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	IC₅₀	37 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD/D835Y mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD/D835Y mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 36638621]
BaF3	IC₅₀	381 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells harboring FLT3-F691L mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-F691L mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 36638621]
BaF3	GI₅₀	4.8 μM Compound: Quizartinib	Growth inhibition of mouse BA/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell-titer-Glo assay Growth inhibition of mouse BA/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell-titer-Glo assay	[PMID: 31513411]
BaF3	IC₅₀	4.94 nM Compound: AC220	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD mutant measured after 72 hrs by MTT assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD mutant measured after 72 hrs by MTT assay	[PMID: 30939008]
BaF3	IC₅₀	49.63 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-D835V mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-D835V mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	IC₅₀	5.41 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-N676D mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-N676D mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	GI₅₀	68.2 nM Compound: AC-220	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	IC₅₀	86 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells harboring FLT3-D835V mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-D835V mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 36638621]
BJ	GI₅₀	> 40 μM Compound: Quizartinib	Cytotoxicity against human BJ cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human BJ cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
CCRF-CEM	GI₅₀	> 40 μM Compound: Quizartinib	Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
CMK	GI₅₀	0.12 μM Compound: 7	Antiproliferative activity against human CMK cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human CMK cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
EOL1	GI₅₀	< 0.0005 μM Compound: Quizartinib	Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
EOL1	IC₅₀	0.0001 nM Compound: 7; AC220	Cytotoxicity against human EOL1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human EOL1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
HCC827	GI₅₀	> 40 μM Compound: Quizartinib	Cytotoxicity against human HCC827 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human HCC827 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
HCC827	GI₅₀	> 5 μM Compound: Quiz	Growth inhibition of human HCC827 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human HCC827 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
HL-60	GI₅₀	> 10 μM Compound: AC220	Growth inhibition of human HL60 cells harboring wild-type FLT3 by CCK8 assay Growth inhibition of human HL60 cells harboring wild-type FLT3 by CCK8 assay	[PMID: 28043794]
HL-60	IC₅₀	> 100 μM Compound: AC220	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
HL-60	GI₅₀	> 3000 nM Compound: 3	Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
HL-60	GI₅₀	0.13 μM Compound: 7	Antiproliferative activity against human HL60 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human HL60 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
HL-60	GI₅₀	1.488 μM Compound: AC220	Growth inhibition of human HL60 cells expressing wild type FLT-3 after 48 hrs by XTT assay Growth inhibition of human HL60 cells expressing wild type FLT-3 after 48 hrs by XTT assay	[PMID: 27187860]
HL-60	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
HL-60	GI₅₀	8.014 μM Compound: AC220	Growth inhibition of human HL60 cells after 48 hrs by XTT assay Growth inhibition of human HL60 cells after 48 hrs by XTT assay	[PMID: 25108079]
IM-9	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human IM-9 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human IM-9 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
K562	GI₅₀	> 10 μM Compound: AC220	Growth inhibition of FLT3 null human K562 cells by CCK8 assay Growth inhibition of FLT3 null human K562 cells by CCK8 assay	[PMID: 28043794]
K562	GI₅₀	> 10 μM Compound: AC220	Growth inhibition of human K562 cells after 48 hrs by XTT assay Growth inhibition of human K562 cells after 48 hrs by XTT assay	[PMID: 25108079]
K562	IC₅₀	> 100 μM Compound: AC220	Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
K562	IC₅₀	> 10000 nM Compound: AC220	Antiproliferative activity against FLT3-deficient human K562 cells after 72 hrs by MTT assay Antiproliferative activity against FLT3-deficient human K562 cells after 72 hrs by MTT assay	[PMID: 27266526]
K562	GI₅₀	> 20 μM Compound: 3, AC220	Inhibition of wild type BCR/ABL in FLT3 deficient human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay Inhibition of wild type BCR/ABL in FLT3 deficient human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26081023]
K562	IC₅₀	> 20 μM Compound: Quizartinib	Antiproliferative activity against human K562 cells assessed as cell death measured after 72 hrs by resazurin dye based assay Antiproliferative activity against human K562 cells assessed as cell death measured after 72 hrs by resazurin dye based assay	[PMID: 34288692]
K562	GI₅₀	> 20 μM Compound: Quiz	Growth inhibition of human K562 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human K562 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
K562	GI₅₀	> 40 μM Compound: Quizartinib	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
K562	IC₅₀	10.33 μM Compound: AC220	Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31614258]
K562	GI₅₀	2.638 μM Compound: AC220	Growth inhibition of human K562 cells after 48 hrs by XTT assay Growth inhibition of human K562 cells after 48 hrs by XTT assay	[PMID: 27187860]
Kasumi 1	GI₅₀	0.064 μM Compound: Quiz	Growth inhibition of human Kasumi-1 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human Kasumi-1 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
KCL-22	IC₅₀	> 100 μM Compound: AC220	Antiproliferative activity against human KCL-22 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human KCL-22 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
KG-1	IC₅₀	0.16 nM Compound: 7; AC220	Cytotoxicity against human KG-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human KG-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
KG-1	GI₅₀	2212.1 nM Compound: 3	Cytotoxicity against human KG1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human KG1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
KG-1	IC₅₀	33.53 μM Compound: AC220	Antiproliferative activity against human KG-1 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human KG-1 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
KG-1a	IC₅₀	> 100 μM Compound: AC220	Antiproliferative activity against human KG-1a cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human KG-1a cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
KG-1a	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human KG-1a cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human KG-1a cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
KMOE-2	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human KMOE-2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human KMOE-2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
L-363	IC₅₀	0.181 nM Compound: 7; AC220	Cytotoxicity against human L-363 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human L-363 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
MCF7	GI₅₀	> 20 μM Compound: Quiz	Growth inhibition of human MCF7 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human MCF7 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
ML-2	IC₅₀	0.419 nM Compound: 7; AC220	Cytotoxicity against human ML-2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human ML-2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
MOLM-13	GI₅₀	< 0.0003 μM Compound: 7	Antiproliferative activity against human MOLM13 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MOLM13 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
MOLM-13	GI₅₀	0.002 μM Compound: Quiz	Growth inhibition of human MOLM13 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human MOLM13 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
MOLM-13	IC₅₀	0.003 μM Compound: AC220	Antiproliferative activity against human MOLM-13 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human MOLM-13 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
MOLM-13	GI₅₀	0.004 μM Compound: 3, AC220	Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26081023]
MOLM-13	IC₅₀	0.007 nM Compound: 7; AC220	Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
MOLM-13	IC₅₀	1.1 nM Compound: Quizartinib	Anticancer activity against human MOLM-13 cells expressing heterogenous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay Anticancer activity against human MOLM-13 cells expressing heterogenous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay	[PMID: 35033885]
MOLM-13	GI₅₀	1.5 nM Compound: 3	Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
MOLM-13	IC₅₀	1.885 nM Compound: AC220	Antiproliferative activity against human MOLM13 cells harboring FLT3-ITD mutant measured after 72 hrs by MTT assay Antiproliferative activity against human MOLM13 cells harboring FLT3-ITD mutant measured after 72 hrs by MTT assay	[PMID: 30939008]
MOLM-13	IC₅₀	2.4 nM Compound: Quizartinib	Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 34583130]
MOLM-14	GI₅₀	< 0.0003 μM Compound: 7	Antiproliferative activity against human MOLM14 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MOLM14 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
MOLM-14	GI₅₀	0.00015 μM Compound: Quizartinib	Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD mutant assessed as cell growth inhibition by resazurin assay Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD mutant assessed as cell growth inhibition by resazurin assay	[PMID: 34479037]
MOLM-14	GI₅₀	0.012 μM Compound: Quizartinib	Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD D835Y mutant assessed as cell growth inhibition by resazurin assay Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD D835Y mutant assessed as cell growth inhibition by resazurin assay	[PMID: 34479037]
MOLM-14	GI₅₀	0.027 μM Compound: Quizartinib	Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD F691L mutant assessed as cell growth inhibition by resazurin assay Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD F691L mutant assessed as cell growth inhibition by resazurin assay	[PMID: 34479037]
MOLM-14	GI₅₀	0.23 nM Compound: 5	Antiproliferative activity against human MOLM14 cells harboring ITD mutant assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MOLM14 cells harboring ITD mutant assessed as cell growth inhibition by MTT assay	[PMID: 32272419]
MOLM-14	GI₅₀	1.35 nM Compound: 5	Antiproliferative activity against wild type human MOLM14 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against wild type human MOLM14 cells assessed as cell growth inhibition by MTT assay	[PMID: 32272419]
MOLM-14	GI₅₀	13.58 nM Compound: 5	Antiproliferative activity against human MOLM14 cells harboring ITD/F691L mutant assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MOLM14 cells harboring ITD/F691L mutant assessed as cell growth inhibition by MTT assay	[PMID: 32272419]
MOLM-14	GI₅₀	6.72 nM Compound: 5	Antiproliferative activity against human MOLM14 cells harboring ITD/D835Y mutant assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MOLM14 cells harboring ITD/D835Y mutant assessed as cell growth inhibition by MTT assay	[PMID: 32272419]
MOLT-4	IC₅₀	50.281 μM Compound: AC220	Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
MONO-MAC-6	IC₅₀	0.004 nM Compound: 7; AC220	Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
MV4-11	GI₅₀	< 0.0003 μM Compound: 7	Antiproliferative activity against human MV4-11 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MV4-11 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
MV4-11	IC₅₀	0 μM Compound: AC220	Antiproliferative activity against human MV4-11 cells harboring FLT3 ITD mutant assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MV4-11 cells harboring FLT3 ITD mutant assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31614258]
MV4-11	IC₅₀	0.002 μM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells assessed as cell death measured after 72 hrs by resazurin dye based assay Antiproliferative activity against human MV4-11 cells assessed as cell death measured after 72 hrs by resazurin dye based assay	[PMID: 34288692]
MV4-11	GI₅₀	0.003 μM Compound: 3, AC220	Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26081023]
MV4-11	GI₅₀	0.003 μM Compound: Quiz	Growth inhibition of human MV4-11 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human MV4-11 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
MV4-11	IC₅₀	0.003 μM Compound: AC220	Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
MV4-11	IC₅₀	0.005 nM Compound: 7; AC220	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
MV4-11	IC₅₀	0.21 nM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 36638621]
MV4-11	IC₅₀	0.452 nM Compound: AC220	Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant measured after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant measured after 72 hrs by MTT assay	[PMID: 30939008]
MV4-11	IC₅₀	0.5 nM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 34583130]
MV4-11	IC₅₀	0.56 nM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay	[PMID: 32659083]
MV4-11	IC₅₀	0.56 nM Compound: 7, AC220	Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay	[PMID: 19754199]
MV4-11	IC₅₀	0.56 nM Compound: AC220	Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay	[PMID: 19654408]
MV4-11	IC₅₀	0.62 nM Compound: Quizartinib	Anticancer activity against human MV4-11 cells expressing homozygous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay Anticancer activity against human MV4-11 cells expressing homozygous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay	[PMID: 35033885]
MV4-11	IC₅₀	0.68 nM Compound: AC220	Cytotoxicity against human MV4-11 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells incubated for 72 hrs by MTT assay	[PMID: 26142317]
MV4-11	GI₅₀	1 nM Compound: 3	Inhibition of FLT3 ITD mutant expressed in human MV4-11 cells assessed as reduction in cell growth incubated for 72 hrs by CCK8 assay Inhibition of FLT3 ITD mutant expressed in human MV4-11 cells assessed as reduction in cell growth incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
MV4-11	GI₅₀	1.103 μM Compound: AC220	Growth inhibition of human MV4-11 cells expressing FLT3-ITD after 48 hrs by XTT assay Growth inhibition of human MV4-11 cells expressing FLT3-ITD after 48 hrs by XTT assay	[PMID: 27187860]
MV4-11	GI₅₀	1.103 μM Compound: AC220	Growth inhibition of human MV4-11 cells harboring FLT3-ITD mutant by XTT assay Growth inhibition of human MV4-11 cells harboring FLT3-ITD mutant by XTT assay	[PMID: 28043794]
MV4-11	IC₅₀	26 nM Compound: AC220	Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant after 72 hrs by MTT assay	[PMID: 27266526]
MV4-11	GI₅₀	3.31 μM Compound: AC220	Growth inhibition of human MV411 cells after 48 hrs by XTT assay Growth inhibition of human MV411 cells after 48 hrs by XTT assay	[PMID: 25108079]
NB-4	GI₅₀	> 3000 nM Compound: 3	Cytotoxicity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
NB-4	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human NB-4 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human NB-4 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
NB-4	GI₅₀	7.3 μM Compound: 7	Antiproliferative activity against human NB4 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human NB4 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
NOMO-1	IC₅₀	> 100 μM Compound: AC220	Antiproliferative activity against human NOMO-1 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human NOMO-1 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
NOMO-1	IC₅₀	0.038 nM Compound: 7; AC220	Cytotoxicity against human NOMO-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human NOMO-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
OCI-AML2	GI₅₀	> 10 μM Compound: 7	Antiproliferative activity against human OCI-AML2 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human OCI-AML2 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
OCI-AML2	IC₅₀	0.45 μM Compound: AC220	Antiproliferative activity against human OCI-AML2 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human OCI-AML2 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
OCI-AML2	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human OCI-AML2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human OCI-AML2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
OCI-AML-5	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human OCI-AML5 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human OCI-AML5 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
OPM-2	IC₅₀	0.056 nM Compound: 7; AC220	Cytotoxicity against human OPM-2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human OPM-2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
PBL	GI₅₀	> 10 μM Compound: AC220	Cytotoxicity in human PBL cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity in human PBL cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35339838]
PBL	GI₅₀	8.6 μM Compound: AC220	Cytotoxicity in phyto-hematoagglutinin induced human PBL cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity in phyto-hematoagglutinin induced human PBL cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35339838]
RPMI-8226	IC₅₀	0.184 nM Compound: 7; AC220	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
RS4-11	IC₅₀	1.1 nM Compound: AC220	Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay	[PMID: 19654408]
RS4-11	IC₅₀	4.2 nM Compound: AC220	Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay	[PMID: 19654408]
Sf21	IC₅₀	26.08 nM Compound: AC220	Inhibition of recombinant human FLT3 expressed in insect Sf21 cells preincubated for 15 mins followed by poly(Glu:Tyr) substrate addition for 30 mins in presence of [gamma-32P]ATP by TR-FRET assay Inhibition of recombinant human FLT3 expressed in insect Sf21 cells preincubated for 15 mins followed by poly(Glu:Tyr) substrate addition for 30 mins in presence of [gamma-32P]ATP by TR-FRET assay	[PMID: 27187860]
Sf9	IC₅₀	> 10 μM Compound: 3, AC220	Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay	[PMID: 26081023]
Sf9	IC₅₀	0.042 μM Compound: Quizartinib	Inhibition of recombinant human 3C cleavage site/N-terminal GST-His6 fused PDGFR alpha C-terminal fragment (Q551 to L1089 residues) harboring V561D mutant expressed in baculovirus infected Sf9 insect cells using AGLT peptide as substrate in presence of [g Inhibition of recombinant human 3C cleavage site/N-terminal GST-His6 fused PDGFR alpha C-terminal fragment (Q551 to L1089 residues) harboring V561D mutant expressed in baculovirus infected Sf9 insect cells using AGLT peptide as substrate in presence of [g	[PMID: 31514019]
Sf9	IC₅₀	0.069 μM Compound: 3, AC220	Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay	[PMID: 26081023]
Sf9	IC₅₀	0.43 μM Compound: 3, AC220	Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay	[PMID: 26081023]
Sf9	IC₅₀	19.8 nM Compound: 3	Inhibition of recombinant human N-terminal GST/His6-tagged FLT3 ITD mutant (571 to 993 residues) expressed in Sf9 cells using Tyr2 peptide as substrate incubated for 1.5 hrs by Z'-LYTE assay Inhibition of recombinant human N-terminal GST/His6-tagged FLT3 ITD mutant (571 to 993 residues) expressed in Sf9 cells using Tyr2 peptide as substrate incubated for 1.5 hrs by Z'-LYTE assay	[PMID: 32832025]
SKM-1	GI₅₀	1.3 μM Compound: 7	Antiproliferative activity against human SKM1 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human SKM1 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
SKM-1	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human SKM-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human SKM-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
TF-1	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human TF-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human TF-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
THP-1	IC₅₀	> 100 μM Compound: AC220	Antiproliferative activity against human THP-1 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human THP-1 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
THP-1	GI₅₀	> 20 μM Compound: Quiz	Growth inhibition of human THP1 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human THP1 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
THP-1	GI₅₀	2.125 μM Compound: AC220	Growth inhibition of human THP1 cells expressing wild type FLT-3 after 48 hrs by XTT assay Growth inhibition of human THP1 cells expressing wild type FLT-3 after 48 hrs by XTT assay	[PMID: 27187860]
THP-1	GI₅₀	2.125 μM Compound: AC220	Growth inhibition of human THP1 cells harboring wild-type FLT3 by XTT assay Growth inhibition of human THP1 cells harboring wild-type FLT3 by XTT assay	[PMID: 28043794]
THP-1	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human THP-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
THP-1	GI₅₀	5.574 μM Compound: AC220	Growth inhibition of human THP1 cells after 48 hrs by XTT assay Growth inhibition of human THP1 cells after 48 hrs by XTT assay	[PMID: 25108079]
U-266	IC₅₀	19.65 nM Compound: 7; AC220	Cytotoxicity against human U-266 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human U-266 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
U-937	GI₅₀	> 20 μM Compound: 3, AC220	Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26081023]
U-937	GI₅₀	> 20 μM Compound: Quiz	Growth inhibition of human U937 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human U937 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
U-937	GI₅₀	> 3000 nM Compound: 3	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
U-937	GI₅₀	1.2 μM Compound: 7	Antiproliferative activity against human U937 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human U937 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
U-937	IC₅₀	8.55 μM Compound: AC220	Antiproliferative activity against human U937 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human U937 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31614258]
WI-38	IC₅₀	> 10000 nM Compound: AC220	Antiproliferative activity against human WI38 cells after 72 hrs by SRB assay Antiproliferative activity against human WI38 cells after 72 hrs by SRB assay	[PMID: 27266526]

In Vitro

Quizartinib (AC220) is a novel compound expressly optimized as a FLT3 inhibitor for the treatment of acute myeloid leukemia (AML). Quizartinib inhibits FLT3-WT and FLT3-ITD autophosphorylation with IC₅₀ of 4.2±0.3 nM and 1.1±0.1 nM, respectively. Quizartinib inhibits MV4-11 and A375 cells with IC₅₀ of 0.56±0.3 nM and >10 000 nM, respectively. Quizartinib inhibits FLT3 with low nanomolar potency in cellular assays and is highly selective when screened against the majority of the human protein kinome^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Quizartinib (AC220) inhibits FLT3 activity in vivo, significantly extends survival in a mouse model of FLT3-ITD AML at doses as low as 1 mg/kg when dosed orally once a day, eradicates tumors in a FLT3-dependent mouse xenograft model at 10 mg/kg, and potently inhibits FLT3 activity in primary patient cells. The oral bioavailability of Quizartinib, determined in rats by comparing oral and intravenous pharmacokinetics at 3 mg/kg, is approximately 40%. A single 10 mg/kg dose of Quizartinib is administered by oral gavage, and mice are killed at 2 time points after dosing, using groups of 4 animals each. Quantitation of total FLT3 and phospho-FLT3 in tumor samples revealed time-dependent inhibition of FLT3 autophosphorylation. FLT3 activity is inhibited by 90% at 2 hours, and 40% at 24 hours after administration. The extent of inhibition therefore correlated well with the expected free Quizartinib plasma levels, based on pharmacokinetic experiments^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

560.67

Formula

C₂₉H₃₂N₆O₄S

CAS No.

950769-58-1

Appearance

Solid

Color

White to light yellow

SMILES

O=C(NC1=NOC(C(C)(C)C)=C1)NC2=CC=C(C=C2)C3=CN4C(SC5=CC(OCCN6CCOCC6)=CC=C45)=N3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : ≥ 33 mg/mL (58.86 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

DMF : 10 mg/mL (17.84 mM; Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7836 mL	8.9179 mL	17.8358 mL
5 mM	0.3567 mL	1.7836 mL	3.5672 mL
10 mM	0.1784 mL	0.8918 mL	1.7836 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMF 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (1.78 mM); Clear solution
Protocol 2

Add each solvent one by one: 10% DMF 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (1.78 mM); Clear solution
Protocol 3

Add each solvent one by one: 10% DMF 90% Corn Oil
Solubility: 1 mg/mL (1.78 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.01%

Select Batch:

Data Sheet (278 KB) SDS (393 KB)

COA (246 KB) HNMR (182 KB) RP-HPLC (240 KB) Elemental Analysis Report (104 KB)

Handling Instructions (2659 KB)

References

[1]. Zarrinkar PP, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 2009, 114(14), 2984-2992. [Content Brief]

[2]. Puissant A, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10;25(2):226-42. [Content Brief]

[3]. Sun X, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019 Dec 24;4:64. [Content Brief]

Kinase Assay ^[1]	KinomeScan kinase binding assays are performed. For the FLT3 assay, a kinase construct that spanned the catalytic domain only (amino acids 592 to 969) is used. This construct does not include the juxtamembrane domain and is designed to measure the intrinsic binding affinity of the open FLT3 active site for inhibitors^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[1]	MV4-11 and RS4;11 cells are cultured in Iscove media with 10% fetal bovine serum (FBS) and RPMI complete with 10% FBS, respectively. For proliferation assays, cells are cultured overnight in low serum media (0.5% FBS), then seeded in a 96-well plate at 40 000 cells per well. Inhibitors (e.g., Quizartinib) are added to the cells and incubated at 37°C for 72 hours. Cell viability is measured using the Cell Titer-Blue Cell Viability Assay. To measure inhibition of FLT3 autophosphorylation, cells are cultured in low serum media (0.5% FBS) overnight and seeded at a density of 400 000 cells per well in a 96-well plate the following day. The cells are incubated with inhibitors (e.g., Quizartinib) for 2 hours at 37°C. To induce FLT3 autophosphorylation in RS4;11 cells, 100 ng/mL FLT3 ligand is added for 15 minutes after the 2-hour compound incubation. Cell lysates are prepared and incubated in 96-well plates precoated with a total FLT3 capture antibody. The coated plates are incubated with either a biotinylated antibody against FLT3 to detect total FLT3 or an antibody against phosphotyrosines to detect FLT3 autophosphorylation. In both cases, a SULFO-tagged streptavidin secondary antibody is used for electrochemiluminescence detection on the Meso Scale Discovery platform^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice^[1] Female NU/NU or severe combined immunodeficient mice are used. Quizartinib (hydrochloride salt) is formulated in 22% hydroxypropyl-β-cyclodextrin, CEP-701 is formulated in 20% gelucire 44/14 in water (vol/vol), MLN-518 and SU 11248 are formulated in 10 mM sodium citrate (pH 3.5), PKC-412 is formulated in 3:1 gelucire 44/14-propylene glycol (vol/vol), and Bay 43-9006 is formulated in 80% PEG-400. Compound concentrations are chosen to deliver the desired dose in a volume of 10 mL/kg. Compounds are administered by oral gavage and plasma samples collected 0.25, 0.5, 1, 2, 4, 6, and 24 hours after dosing. To collect plasma samples, eye bleeds (150 μL) are taken semilongitudinally using 3 groups of 3 animals each, taking 2 to 3 time points per animal to obtain a total of 3 independent plasma concentration time courses. Plasma samples and controls (25 μL) are extracted with 4 volumes of acetonitrile containing an internal standard and analyzed by liquid chromatography tandem mass spectrometry. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Zarrinkar PP, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 2009, 114(14), 2984-2992. [Content Brief] [2]. Puissant A, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10;25(2):226-42. [Content Brief] [3]. Sun X, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019 Dec 24;4:64. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMF / DMSO	1 mM	1.7836 mL	8.9179 mL	17.8358 mL	44.5895 mL
	5 mM	0.3567 mL	1.7836 mL	3.5672 mL	8.9179 mL
	10 mM	0.1784 mL	0.8918 mL	1.7836 mL	4.4590 mL
	15 mM	0.1189 mL	0.5945 mL	1.1891 mL	2.9726 mL
DMSO	20 mM	0.0892 mL	0.4459 mL	0.8918 mL	2.2295 mL
	25 mM	0.0713 mL	0.3567 mL	0.7134 mL	1.7836 mL
	30 mM	0.0595 mL	0.2973 mL	0.5945 mL	1.4863 mL
	40 mM	0.0446 mL	0.2229 mL	0.4459 mL	1.1147 mL
	50 mM	0.0357 mL	0.1784 mL	0.3567 mL	0.8918 mL

Quizartinib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Quizartinib (Synonyms: AC220; AC708)

Customer Review

Other Forms of Quizartinib:

31 Publications Citing Use of MCE Quizartinib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Quizartinib Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Quizartinib (Synonyms: AC220; AC708)

Customer Review

Other Forms of Quizartinib:

Quizartinib Related Antibodies

31 Publications Citing Use of MCE Quizartinib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Quizartinib Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Quizartinib Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report